Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2].
in vivo
Lerdelimumab (100 μL, 1 mg/mL; subconjunctival injection; on days 2, 3, 4, 7, 9, 11 and 14 after surgery) significantly improves glaucoma surgical outcome and reduces the risk of corneal side effects[1].
References
[1] Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401. DOI:10.1167/iovs.02-0978 [2] Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. PMID:12091431
